These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2828674)

  • 1. Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.
    Ray R; Glaze BJ; Compans RW
    J Virol; 1988 Mar; 62(3):783-7. PubMed ID: 2828674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of monoclonal antibodies against parainfluenza virus type 3-induced brain infection in hamsters.
    Rydbeck R; Löve A; Norrby E
    J Gen Virol; 1988 May; 69 ( Pt 5)():1019-24. PubMed ID: 2836547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
    van Wyke Coelingh KL; Winter CC; Tierney EL; Hall SL; London WT; Kim HW; Chanock RM; Murphy BR
    J Virol; 1990 Aug; 64(8):3833-43. PubMed ID: 1695256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity.
    Paterson RG; Lamb RA; Moss B; Murphy BR
    J Virol; 1987 Jun; 61(6):1972-7. PubMed ID: 3573154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human parainfluenza virus induces a type-specific protective immune response.
    Ray R; Matsuoka Y; Burnett TL; Glaze BJ; Compans RW
    J Infect Dis; 1990 Sep; 162(3):746-9. PubMed ID: 2167342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoproteins of human parainfluenza virus type 3: characterization and evaluation as a subunit vaccine.
    Ray R; Brown VE; Compans RW
    J Infect Dis; 1985 Dec; 152(6):1219-30. PubMed ID: 2999259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoproteins of human parainfluenza virus type 3: affinity purification, antigenic characterization and reconstitution into lipid vesicles.
    Ray R; Compans RW
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():409-18. PubMed ID: 3029283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
    Spriggs MK; Murphy BR; Prince GA; Olmsted RA; Collins PL
    J Virol; 1987 Nov; 61(11):3416-23. PubMed ID: 2822951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microencapsulated human parainfluenza virus induces a protective immune response.
    Ray R; Novak M; Duncan JD; Matsuoka Y; Compans RW
    J Infect Dis; 1993 Mar; 167(3):752-5. PubMed ID: 8382726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3.
    Ray R; Glaze BJ; Moldoveanu Z; Compans RW
    J Infect Dis; 1988 Apr; 157(4):648-54. PubMed ID: 2831281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children.
    Kasel JA; Frank AL; Keitel WA; Taber LH; Glezen WP
    J Virol; 1984 Dec; 52(3):828-32. PubMed ID: 6092715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological relationships between mumps virus and parainfluenza viruses studied with monoclonal antibodies.
    Orvell C; Rydbeck R; Löve A
    J Gen Virol; 1986 Sep; 67 ( Pt 9)():1929-39. PubMed ID: 3018131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.